Citations

Showing 10 of 108104 citations.

The efficacy of posterior wall isolation in atrial fibrillation ablation: A systematic review and meta‐analysis of randomized controlled trials
Kanitsoraphan, Chanavuth , Techorueangwiwat, Chol, Kewcharoen, Jakrin , Mekritthikrai, Raktham , Shah, Parthav , Masry, Hicham El , Kewcharoen, Jakrin , El Masry, Hicham , Kanitsoraphan, Chanavuth , Rattanawong, Pattara , Prasitlumkum, Narut

Mayo Clinic

Journal of Arrhythmia | March 18, 2022 | Volume: 38 | Issue: 3 | Pages: 275-286

10.1002/joa3.12698 | PMID 35785381 Get It

AbstractBackgroundPosterior wall isolation (PWI) is an emerging approach in atrial fibrillation (AF) ablation, yet its efficacy remains controversial. This is the first meta‐analysis of randomized controlled trials (RCT) to evaluate the efficacy of PWI in AF ablation.ObjectiveTo assess the efficacy of PWI in reducing atrial arrhythmia recurrence following initial AF ablation at long‐term follow‐ups when compared to conventional methods.MethodsWe conducted a literature search from inception through September 2021 in EMBASE and MEDLINE databases. We included RCTs that compared outcomes in PWI and conventional approaches of AF ablation. Data from each study were combined using the random‐effects, generic inverse variance method of DerSimonian and Laird to calculate odds ratio (OR), and 95% confidence interval (CI).ResultsEight RCT from 2009 to 2020, including 1024 AF patients, were included. PWI did not decrease overall atrial arrhythmias recurrence (RR 0.96, 95% CI:0.88–1.05, I2 = 31.6%, p‐value 0.393). However, the pooled analysis showed a significant decrease in AF recurrence in PWI compared to controlled approaches (RR 0.88, 95% CI:0.81–0.96, I2 = 48.2%, p‐value .004). In the subgroup analysis, PWI significantly decreased AF recurrence in the studies that included only persistent AF (RR = 0.89, 95% CI:0.80–0.98, I2 = 65.2%, p‐value .014). PWI significantly decreased AF recurrence when compared to PVI with roof line (RR 0.84, 95% CI 0.74–0.95, I2 0.00%, p‐value .008).ConclusionOur study suggests that adding PWI significantly decreased AF recurrence in patients with persistent AF compared to controlled approaches. It highlights the importance of considering PWI during the initial procedure in this patient population.
Red herring pathogenic variants: a case report of premature ventricular contraction-triggered ventricular fibrillation with an incidental pathogenic LMNA variant
Garmany, Ramin , Neves, Raquel , Ali‐Ahmed, Fatima , Tester, David J. , Cannon, Bryan C. , Giudicessi, John R. , Ackerman, Michael J. , Neves, Raquel Almeida Lopes , Garmany, Ramin

Mayo Clinic

European Heart Journal - Case Reports | March 17, 2022 | Volume: 6 | Issue: 5 | Pages: No page available

10.1093/ehjcr/ytac115 | PMID 35528128 Get It

Abstract Background Pathogenic variants in the lamin A/C gene (LMNA) can lead to a wide range of phenotypes from dilated and arrhythmogenic cardiomyopathies and conduction abnormalities to partial lipodystrophies. This case highlights a coincidental pathogenic LMNA variant identified in a patient with sudden cardiac arrest (SCA). We demonstrate the need for careful interpretation of pathogenic variants identified in cardiomyopathy genes by highlighting a case in which a coincidental pathogenic LMNA variant was found in a patient with premature ventricular complex (PVC)-induced ventricular fibrillation (VF). Case summary We present the case of a 16-year-old male with SCA secondary to VF. Genetic testing identified a maternally inherited pathogenic variant in LMNA annotated c.1961dup; p.T655Nfs*49. The patient received an implantable cardiac defibrillator and was discharged on nadolol. The patient’s two brothers were also variant-positive. However, the patient and both brothers had normal chamber dimensions on echocardiogram and no late gadolinium enhancement on cardiac magnetic resonance imaging. The family members with the variant were recommended to have prophylactic implantable cardiac defibrillators and thus sought a second opinion. The patient received an appropriate shock and device interrogation identified PVCs. Electrophysiology study identified PVC-induced VF which was ablated with no recurrent ventricular arrhythmias/implantable cardioverter defibrillator therapies over 8 months of follow-up. Although the variant in LMNA could lead to cardiac arrest, the clinical phenotype was consistent with a non-genetic aetiology. The family members were told to have periodic cardiac evaluation. Discussion This case demonstrates the identification of a coincidental pathogenic variant in a cardiomyopathy gene in a patient with cardiac arrest. Although this variant could lead to cardiomyopathy, it appears the cardiac arrest was not due to the pathogenic variant. This highlights the need to consider the clinical phenotype when interpreting genetic test results for cardiomyopathies even in the presence of a positive genetic test result.
A Case Report of “Propofol Frenzy”: Anesthetic Considerations for a Severe Propofol-Induced Neuroexcitation Reaction
Panchamia, Jason K., Amundson, Adam W., Demirci, Onur, Braksick, Sherri A., Wijdicks, Eelco F., Amundson, Adam W. , Panchamia, Jason K., Demirci, Onur, Braksick, Sherri A., Wijdicks, Eelco F.

Mayo Clinic

A&A Practice | March 17, 2022 | Volume: 16 | Issue: 3 | Pages: e01569

10.1213/xaa.0000000000001569 | PMID 35299226 Get It

Propofol “frenzy” is considered a severe propofol-induced neuroexcitatory reaction involving nonepileptic spells of extremity thrashing, marked agitation, irregular eye movements, and impaired consciousness. Patients with propofol neuroexcitation present unique challenges for anesthesia providers due to underrecognition, lack of diagnostic tests, and differentiating from other comparable disorders that require medications that can exacerbate symptoms. We present a case of a healthy young patient whose postoperative course was complicated by propofol frenzy and functional limb paralysis following hip surgery with a spinal anesthetic and propofol sedation. This case highlights anesthesia considerations for propofol frenzy and discusses dexmedetomidine as a promising modality for prompt management.
Finding a consensus on time‐to‐event endpoints definitions in marginal zone lymphoma: A Delphi method
Nowakowski, Grzegorz S. , Zucca, Emanuele , Thiéblemont, Catherine , Bommier, Côme , Zucca, Emanuele , Lambert, Jérôme

Mayo Clinic

Hematological Oncology | March 17, 2022 | Volume: 40 | Issue: 5 | Pages: 1086-1089

10.1002/hon.2988 | PMID 35299287 Get It

Abstract A recent systematic review reported that trials involving patients with marginal zone lymphoma (MZL) show marked heterogeneity both in the choice and definitions of primary and secondary endpoints, thus hampering comparability between trials. The main objective of this study was to reach consensus, through a Delphi process, on the definitions of four time‐to‐event endpoints in MZL trials, by surveying clinicians and methodologists involved in the conduct of clinical trials including patients with MZL. We polled a panel of leading international experts involved in MZL trials by means of self‐administered sequential questionnaires in 2021. Of these 105 experts, 62 responded to the Round 1 questionnaire regarding the definitions of progression‐free survival (PFS), event‐free survival (EFS), time‐to‐failure (TTF), and time‐to‐next‐treatment (TTNT). Afterward, we therefore focused the Round 2 and 3 questionnaires among principal investigators, coinvestigators, and trial methodologists. Consensus was reached when there was a >80% agreement on all potential events (11 choices) of each endpoint. Participants in our survey reached consensus on three of the four time‐to‐event endpoints definitions. Consensus was reached on the definitions of PFS and TTNT after Round 1, of TTF after Round 2, and was not reached for EFS after Round 3. The disagreement concerned the event “treatment discontinuation” in EFS definition. The main interest of our study was to elicit investigator's interest in the importance of consistently defining endpoints in MZL trials and to highlight that composite endpoints should not be encouraged. Fifteen years after the last consensus statement on time‐to‐event endpoints definitions issued in Lugano (2007), both the review of literature and survey of international investigators agree on the inconsistency of endpoints definitions used within the MZL community. Hopefully, revised standardized definitions of endpoints shall be provided at the upcoming International Conference on Malignant Lymphoma in 2023.
The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats
Hosseinzadeh, Rezvan , Liang, Jackson J. , Mansouri, Razieh, Moghadamnia, Ali Akbar , Liang, Jackson , Barary, Mohammad , Sio, Terence T. , Hosseini, Mohammad, Kazemi, Sohrab

Mayo Clinic

No container title available | March 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1359440/v2 Get It

Abstract Background 5- Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used in treating solid tumors, and the 5-FU-induced cardiotoxicity is the second cause of cardiotoxicity induced by chemotherapeutic drugs. Propolis (Pro) has vigorous anti-inflammatory activity. Its cardio-protective characteristic against doxorubicin-induced cardiotoxicity was previously proven. The current study aimed to appraise the effect of Pro on 5-FU-induced cardiotoxicity in rats. Methods Twenty-four male Wistar rats were divided into four groups: Control, 5-FU, 5-FU + Pro 250 mg/kg, and 5-FU + Colchicine (CLC) 5 mg/kg. Different hematological, serological, biochemical, histopathological, and molecular assays were performed to assess the study aim. Moreover, rat myocardium (H9C2(2 − 1)) and human skin fibroblast (HNFF-P18) cell lines were also used to assess this protective effect in-vitro. Results 5-FU resulted in significant cardiotoxicity represented by an increase in malondialdehyde (MDA) levels, cyclooxygenase-2 (COX-2), and tumor necrosis factor-α (TNF-α) expression, cardiac enzyme levels, and histopathological degenerations. 5-FU treatment also decreased bodyweight, total anti-oxidant capacity (TAC), catalase (CAT) levels, blood cell counts, and hemoglobin (Hb) levels. In addition, 5-FU disrupted ECG parameters, including increased elevation in the ST-segment and increased QRS complex and QTc duration. Treating with Pro reduced oxidative stress, cardiac enzymes, histopathological degenerations, and COX-2 expression in cardiac tissue alleviated ECG disturbances and increased the number of blood cells and TAC levels. Moreover, 5-FU-induced bodyweight loss was ameliorated after treatment with Pro. Conclusion Our results demonstrated that treatment with Pro significantly improved cardiotoxicity induced by 5-FU in rats.
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
Kehl, Kenneth L. , Zahrieh, David M. , Hillman, Shauna L., Tan, Angelina D., Oxnard, Geoffrey R. , Gillaspie, Erin A. , Wigle, Dennis A. , Malik, Shakun , Stinchcombe, Thomas E. , Govindan, Ramaswamy , Mandrekar, Sumithra J. , Osarogiagbon, Raymond U. , Kozono, David , Wigle, Dennis, Osarogiagbon, Raymond U , Kozono, David E , Govindan, Ramaswamy , Yang, Ping , Sands, Jacob , Ramalingam, Suresh S. , Kelly, Karen

Mayo Clinic

JAMA Oncology | March 17, 2022 | Volume: 8 | Issue: 5 | Pages: 717

10.1001/jamaoncol.2022.0039 | PMID 35297944 Get It

American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham, Neena S. , Douketis, James D. , Laine, Loren , Telford, Jennifer J. , Telford, Jennifer J , Barkun, Alan , Sauer, Bryan G. , Noseworthy, Peter A. , Leontiadis, Grigorios I.

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 17, 2022 | Volume: 5 | Issue: 2 | Pages: 100-101

10.1093/jcag/gwac010 | PMID 35368325 Get It

AbstractWe conducted systematic reviews of predefined clinical questions and used the Grading of Recommendations, Assessment, Development and Evaluations approach to develop recommendations for the periendoscopic management of anticoagulant and antiplatelet drugs during acute gastrointestinal (GI) bleeding and the elective endoscopic setting. The following recommendations target patients presenting with acute GI bleeding: For patients on warfarin, we suggest against giving fresh frozen plasma or vitamin K; if needed, we suggest prothrombin complex concentrate (PCC) compared with fresh frozen plasma administration; for patients on direct oral anticoagulants (DOACs), we suggest against PCC administration; if on dabigatran, we suggest against the administration of idarucizumab, and if on rivaroxaban or apixaban, we suggest against andexanet alfa administration; for patients on antiplatelet agents, we suggest against platelet transfusions; and for patients on cardiac acetylsalicylic acid (ASA) for secondary prevention, we suggest against holding it, but if the ASA has been interrupted, we suggest resumption on the day hemostasis is endoscopically confirmed. The following recommendations target patients in the elective (planned) endoscopy setting: For patients on warfarin, we suggest continuation as opposed to temporary interruption (1–7 days), but if it is held for procedures with high risk of GI bleeding, we suggest against bridging anticoagulation unless the patient has a mechanical heart valve; for patients on DOACs, we suggest temporarily interrupting rather than continuing these; for patients on dual antiplatelet therapy for secondary prevention, we suggest temporary interruption of the P2Y12 receptor inhibitor while continuing ASA; and if on cardiac ASA monotherapy for secondary prevention, we suggest against its interruption. Evidence was insufficient in the following settings to permit recommendations. With acute GI bleeding in patients on warfarin, we could not recommend for or against PCC administration when compared with placebo. In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y12 receptor inhibitor for patients on a single P2Y12 inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1–7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y12 receptor inhibitor drugs because of insufficient evidence.
Incisional Biopsy Technique Is Associated With Decreased Overall Survival for Cutaneous Melanoma
Liszewski, Walter, Stewart, Jacob R., Vidal, Nahid Y., Demer, Addison M., Liszewski, Walter, Stewart, Jacob R., Vidal, Nahid Y., Demer, Addison M.

Mayo Clinic

Dermatologic Surgery | March 17, 2022 | Volume: 48 | Issue: 5 | Pages: 486-491

10.1097/dss.0000000000003430 | PMID 35298451 Get It

BACKGROUND Previous studies examining melanoma biopsy technique have not demonstrated an effect on overall survival. OBJECTIVE To examine overall survival of patients with cutaneous melanoma diagnosed by shave, punch, incisional, or excisional techniques from the National Cancer Database (NCDB). MATERIALS AND METHODS Melanoma data from the 2004 to 2016 NCDB data set were analyzed. A Cox proportional hazards model was constructed to assess the risk of 5-year all-cause mortality. RESULTS In total, 42,272 cases of melanoma were reviewed, with 27,899 (66%) diagnosed by shave biopsy, 8,823 (20.9%) by punch biopsy, and 5,550 (13.1%) by incisional biopsy. Both the univariate and multivariate analyses demonstrated that tumors diagnosed by incisional biopsy had significantly (p = .001) lower overall 5-year survival compared with shave techniques (hazard ratio [HR] = 1.140, 95% confidence interval [CI] 1.055 to 1.231). We found no difference (p = .109) between shave and punch biopsy techniques (HR 1.062, 95% CI 0.987–1.142) or between punch and incisional techniques (HR 1.074, 95% CI 0.979–1.177, p = .131). CONCLUSION Incisional biopsies were associated with decreased overall 5-year survival in the NCDB. No difference was observed between shave and punch biopsy techniques. These findings support current melanoma management guidelines.